The hepatitis B vaccine market size in the 7 major markets was valued at USD 4.8 billion in 2023, driven by the increasing incidence of hepatitis B cases across the major markets. The market is expected to grow at a CAGR of 4.8% during the forecast period of 2024-2032, with the values likely to rise from USD 5 billion in 2024 to USD 7.3 billion by 2032.
Hepatitis B is a liver infection caused by the hepatitis B virus. The infection may be long term (chronic) or short term (acute). Chronic hepatitis B can put people at the risk of death from cirrhosis and liver cancer. It can spread through fluid transfusion from an infected person and even transfer from a mother to the child. Hepatitis B vaccinations play a crucial role in minimizing the risk of this fatal disease. The vaccinations can protect against the infection for at least 20 years.
With notable advancements within the range vaccines available, the hepatitis B vaccine market value has risen significantly in the recent years. Some of the notable authorized hepatis B vaccinations include Engerix-B, a noninfectious recombinant DNA vaccine, Heplisav-B®, Recombivax HB, and Twinrix hepatitis vaccine, which is indicated for both hepatitis A and B, adding versatility to the market.
The hepatitis B vaccine market growth is likely to expediate with the on-going investigations. The U.S. CDC's initiative for Universal Hepatitis B Vaccination in Adults aged 19–59 signals a broader adoption trend. VTP-300, the hepatits B vaccination by Vaccitech is undergoing trials and has shown positive outcomes, indicating its breakthrough in upcoming years.
GSK plc's upcoming presentation at The Liver Meeting® 2023 is set to unveil insights from the B-Together phase IIb trial on bepirovirsen. It is an antisense oligonucleotide for chronic hepatitis B showcasing encouraging outcomes, especially in combination with pegylated interferon alfa. The trial evaluates the sequential regimen's efficacy in treating CHB infection, reducing hepatitis B surface antigen, and lowering virus DNA in the blood. Such developments hold a promising future for the vaccinations market in the forecast period.
Market Breakup by Type
Market Breakup by Age
Market Breakup by End User
Market Breakup by Region
The World Health Organization estimates that the world population may suffer with 1.5 million new hepatitis B infections every year, as a result, the hepatitis B vaccine market demand has increased significantly. North America, particularly the United States, has dominated the market in the historical period. The market share can be accredited to the presence of key market players offering advanced vaccines. The region's well-established healthcare infrastructure and high awareness levels have further propelled market growth.
European market has also expanded with its robust healthcare system and proactive vaccination drives. The ongoing research and development activities by pharmaceutical companies, along with collaborations and partnerships among research institutions, continue to drive innovation in the region.
Going forward, Asia Pacific and Africa are poised to become pivotal centres for hepatitis B vaccine market share. These regions face a higher burden of hepatitis B infections, demanding high vaccination initiatives. Asia Pacific, being home to densely populated countries with emerging economies, is witnessing a surge in healthcare awareness and infrastructure development. The rising prevalence of hepatitis B in these regions amplifies the urgency for vaccination programs.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Type||
|Breakup by Age||
|Breakup by End User||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Hepatitis B Disease Overview
3.1 Guidelines and Stages
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Hepatitis B Disease Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Hepatitis B Disease Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Hepatitis B Disease Epidemiology Forecast (2017-2032)
5.3.1 Germany Hepatitis B Disease Epidemiology Forecast (2017-2032)
5.3.2 France Hepatitis B Disease Epidemiology Forecast (2017-2032)
5.3.3 Italy Hepatitis B Disease Epidemiology Forecast (2017-2032)
5.3.4 Spain Hepatitis B Disease Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Hepatitis B Disease Epidemiology Forecast (2017-2032)
5.4 Japan Hepatitis B Disease Epidemiology Forecast (2017-2032)
6 Hepatitis B Vaccine Market Overview – 7MM
6.1 Hepatitis B Vaccine Market Historical Value (2017-2023)
6.2 Hepatitis B Vaccine Market Forecast Value (2024-2032)
7 Hepatitis B Vaccine Market Landscape – 7MM
7.1 Hepatitis B Vaccine: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Hepatitis B Vaccine: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Treatment Type
7.2.3 Analysis by Diagnosis Method
8 Hepatitis B Vaccine Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Hepatitis B Vaccine Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Hepatitis B Vaccine Market Segmentation – 7MM
11.1 Hepatitis B Vaccine Market by Type
11.1.1 Market Overview
11.1.2 Single Antigen
11.2 Hepatitis B Vaccine Market by Age
11.2.1 Market Overview
11.3 Hepatitis B Vaccine Market by End User
11.3.1 Market Overview
11.3.4 Vaccination Centres
11.4 Hepatitis B Vaccine Market by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
22.214.171.124 United Kingdom
12 United States Hepatitis B Vaccine Market
12.1 Hepatitis B Vaccine Market Historical Value (2017-2023)
12.2 Hepatitis B Vaccine Market Forecast Value (2024-2032)
12.3 Hepatitis B Vaccine Market by Type
12.4 Hepatitis B Vaccine Market by Treatment Type
13 EU-4 and United Kingdom Hepatitis B Vaccine Market
13.1 Hepatitis B Vaccine Market Historical Value (2017-2023)
13.2 Hepatitis B Vaccine Market Forecast Value (2024-2032)
13.3 Germany Hepatitis B Vaccine Market Overview
13.3.1 Hepatitis B Vaccine Market by Type
13.3.2 Hepatitis B Vaccine Market by Treatment Type
13.4 France Hepatitis B Vaccine Market Overview
13.4.1 Hepatitis B Vaccine Market by Type
13.4.2 Hepatitis B Vaccine Market by Treatment Type
13.5 Italy Hepatitis B Vaccine Market Overview
13.5.1 Hepatitis B Vaccine Market by Type
13.5.2 Hepatitis B Vaccine Market by Treatment Type
13.6 Spain Hepatitis B Vaccine Market Overview
13.6.1 Hepatitis B Vaccine Market by Type
13.6.2 Hepatitis B Vaccine Market by Treatment Type
13.7 United Kingdom Hepatitis B Vaccine Market Overview
13.7.1 Hepatitis B Vaccine Market by Type
13.7.2 Hepatitis B Vaccine Market by Treatment Type
14 Japan Hepatitis B Vaccine Market
14.1 Hepatitis B Vaccine Market Historical Value (2017-2023)
14.2 Hepatitis B Vaccine Market Forecast Value (2024-2032)
14.3 Hepatitis B Vaccine Market by Type
14.4 Hepatitis B Vaccine Market by Treatment Type
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 INDIA CDSCO
15.1.4 JAPAN PMDA
16 Clinical Trials Analysis
16.1 Analysis by Trial Registration Year
16.2 Analysis by Trial Status
16.3 Analysis by Trial Phase
16.4 Analysis by Therapeutic Area
16.5 Analysis by Geography
17 Funding and Investment Analysis
17.1 Analysis by Funding Instances
17.2 Analysis by Type of Funding
17.3 Analysis by Funding Amount
17.4 Analysis by Leading Players
17.5 Analysis by Leading Investors
17.6 Analysis by Geography
18 Partnership and Collaborations Analysis
18.1 Analysis by Partnership Instances
18.2 Analysis by Type of Partnership
18.3 Analysis by Leading Players
18.4 Analysis by Geography
19 Supplier Landscape
19.1 Merck & Co.,Inc.
19.1.1 Financial Analysis
19.1.2 Product Portfolio
19.1.3 Demographic Reach and Achievements
19.1.4 Mergers and Acquisitions
19.2 Sanofi S.A.
19.2.1 Financial Analysis
19.2.2 Product Portfolio
19.2.3 Demographic Reach and Achievements
19.2.4 Mergers and Acquisitions
19.3 Dynavax Technologies Corporation
19.3.1 Financial Analysis
19.3.2 Product Portfolio
19.3.3 Demographic Reach and Achievements
19.3.4 Mergers and Acquisitions
19.4 GlaxoSmithKline plc.
19.4.1 Financial Analysis
19.4.2 Product Portfolio
19.4.3 Demographic Reach and Achievements
19.4.4 Mergers and Acquisitions
19.5 Pancea Biotech Ltd
19.5.1 Financial Analysis
19.5.2 Product Portfolio
19.5.3 Demographic Reach and Achievements
19.5.4 Mergers and Acquisitions
19.6 Beijing Tiantan Biological Products Co., Ltd.
19.6.1 Financial Analysis
19.6.2 Product Portfolio
19.6.3 Demographic Reach and Achievements
19.6.4 Mergers and Acquisitions
19.7 VBI Vaccines Inc.
19.7.1 Financial Analysis
19.7.2 Product Portfolio
19.7.3 Demographic Reach and Achievements
19.7.4 Mergers and Acquisitions
19.8 Emmy Vaccine Co.,Ltd.
19.8.1 Financial Analysis
19.8.2 Product Portfolio
19.8.3 Demographic Reach and Achievements
19.8.4 Mergers and Acquisitions
19.9 Beijing Minhai Biological Technology Co., Ltd.
19.9.1 Financial Analysis
19.9.2 Product Portfolio
19.9.3 Demographic Reach and Achievements
19.9.4 Mergers and Acquisitions
20 Hepatitis B Vaccine - Distribution Model (Additional Insight)
20.2 Potential Distributors
20.3 Key Parameters for Distribution Partner Assessment
21 Key Opinion Leaders (KOL) Insights (Additional Insight)
22 Company Competitiveness Analysis (Additional Insight)
22.1 Very Small Companies
22.2 Small Companies
22.3 Mid-Sized Companies
22.4 Large Companies
22.5 Very Large Companies
23 Payment Methods (Additional Insight)
23.1 Government Funded
23.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The market attained a value of about USD 4.8 billion in 2023, driven by the increasing prevalence of hepatitis B cases across the7 major markets.
The market is anticipated to grow at a CAGR of 4.8% during the forecast period of 2024-2032, likely to reach a market value of USD 7.3 billion by 2032.
The market demand has increased with the advent of highly efficient vaccinations such as Engerix-B, Heplisav-B®, Recombivax HB, and Twinrix hepatitis vaccine.
The current market trend is marked by the ongoing investigation on vaccines for adults falling the age group of 19-59. One such example is VTP-300 by Vaccitech, which is currently in trials and displayed positive results.
Single antigen and combination are common Hepatitis B vaccine types.
They are available for pediatrics as well as adults.
Major end users include hospitals, clinics, and vaccination centres.
The major regions of the market include United States, EU-4 and the United Kingdom, Japan. EU-4 includes Germany, France, Italy, and Spain.
Key players involved in the market are Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc., Pancea Biotech Ltd., Beijing Tiantan Biological Products Co., Ltd., VBI Vaccines Inc., Emmy Vaccine Co. Ltd., Beijing Minhai Biological Technology Co., Ltd., and Dynavax Technologies Corporation.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.